US Patent

US12472194 — Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same

Method of Use · Assigned to AstraZeneca AB · Expires 2039-07-18 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating and/or preventing heart failure with preserved ejection fraction using dapagliflozin and compositions containing it.

USPTO Abstract

Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.

Drugs covered by this patent

Farxiga (DAPAGLIFLOZIN) · AstraZeneca

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4346`	—	Farxiga

Patent Metadata

Patent number: US12472194
Jurisdiction: US
Classification: Method of Use
Expires: 2039-07-18
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.